CORRIGENDUM: Safety and Effectiveness of Apixaban in Japanese Patients With Venous Thromboembolism in Clinical Practice　― A Post-Marketing Surveillance ―

The authors apologize for the errors in the Results section. Corrections are shown below.

1) Page 2203, Table 2

2) Page 2204, right column, lines 16–19

Incorrect:

A total of 725 (64.8%) patients were initiated apixaban on the 10 mg BID dose; 331 (29.6%) were initiated on the 5 mg BID dose; and 63 (5.6%) were initiated on other doses, including 2.5 mg BID (58 patients),

Corrected:

A total of 725 (64.8%) patients were initiated apixaban on the 10 mg BID dose; 328 (29.3%) were initiated on the 5 mg BID dose; and 66 (5.9%) were initiated on other doses, including 2.5 mg BID (61 patients),

3) Page 2205, left column, lines 7–11

Incorrect:

The rates of any bleeding and major bleeding in patients initiated on apixaban 10 mg BID were 7.72% (56/725) and 3.86% (28/725), respectively, and in patients initiated on apixaban 5 mg BID were 4.53% (15/331) and 2.72% (9/331), respectively.

Corrected:

The rates of any bleeding and major bleeding in patients initiated on apixaban 10 mg BID were 7.72% (56/725) and 3.86% (28/725), respectively, and in patients initiated on apixaban 5 mg BID were 4.57% (15/328) and 2.74% (9/328), respectively.